Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1M | 0 | 0 | 0 | 75K |
| Gross Profit | -3M | -1M | -1M | -1M | 75K |
| Operating Income | -13M | -10M | -21M | -34M | -14M |
| EBITDA | -12M | -9M | -20M | -36M | -13M |
| Net Income | -12M | -11M | -21M | -38M | -13M |
| EPS (Diluted) | — | — | — | — | — |
Technology
Live Price
Offline$16.40
+0.00% today
Window Change
+132.62%
Window
Jun 23, 2025 → Apr 24, 2026
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 212 bars · Jun 23, 2025 → Apr 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Coeptis Therapeutics Holdings, Inc. (COEP) is a Technology stock with a market cap of $57.63M and listed on NASDAQ. The stock last traded around $16.40 and up 132.6% across the available one-year price window (Jun 23, 2025 → Apr 24, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +50.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +50.3%, free cash flow -29.4% with operating margin -956.9% and ROIC -55.7%. Valuation already assumes a fairly strong business story at price/sales 42.3. Stock Foundry combines COEP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Technology peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
COEP
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
COEP Max Drawdown
-44.68%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for COEP and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$75.0K
FY Net Income
-$13.4M
+64.2% YoY
Free Cash Flow
-$6.2M
-61.0% YoY
Revenue Growth
+0.0%
EPS Growth
+50.3%
Gross Margin
-207.8%
Net Margin
-611.1%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1M | 0 | 0 | 0 | 75K |
| Gross Profit | -3M | -1M | -1M | -1M | 75K |
| Operating Income | -13M | -10M | -21M | -34M | -14M |
| EBITDA | -12M | -9M | -20M | -36M | -13M |
| Net Income | -12M | -11M | -21M | -38M | -13M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 6M | 533K | 1M | 4M | 2M |
| Total Assets | 20M | 9M | 8M | 8M | 7M |
| Total Liabilities | 2M | 5M | 4M | 3M | 4M |
| Shareholder Equity | 17M | 3M | 4M | 4M | 2M |
| Total Debt | 269K | 1M | 1M | 2M | 4M |
| Net Debt | -5M | 866K | -245K | -2M | 2M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
4M
-15.8% YoY
Capital Expenditures
2M
Free Cash Flow
6M
-61.0% YoY
Key ratios
Gross Margin
-207.8%
Operating Margin
-956.9%
Net Margin
-611.1%
ROE
-78.8%
Debt / Equity
0.02x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.